Product
Ladarixin
Aliases
allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, LDX
8 clinical trials
6 indications
Indication
Type 1 DiabetesIndication
ConditionIndication
Diabetes MellitusIndication
Insulin-DependentIndication
New-onset Type 1 DiabetesIndication
Advanced Non-small Cell Lung CancerClinical trial
Ladarixin 400 mg Twice a Day as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Overweight Insulin-resistant Type 1 Diabetic PatientsStatus: Withdrawn, Estimated PCD: 2023-06-01
Clinical trial
Randomized, Placebo-controlled, Double-blinded, 2-parallel Arm, Clinical Trial Evaluating Ladarixin 400 mg Bid as Adjunctive Therapy to Improve Glycemic Control in Overweight Insulin-resistant Patients With Type 1 Diabetes.Status: Terminated, Estimated PCD: 2023-09-18
Clinical trial
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy - Safety of 400 mg Twice a Day Oral Ladarixin in Pts With Recent Onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY)Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Influence of Food on the Oral Bioavailability of Ladarixin 200 mg Capsule in Healthy Volunteers of Both Sexes. A Single Dose (400 mg), Randomized, Open Label, Two-Way Crossover StudyStatus: Completed, Estimated PCD: 2020-12-09
Clinical trial
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 DiabetesStatus: Completed, Estimated PCD: 2019-05-15
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.Status: Terminated, Estimated PCD: 2023-04-27
Clinical trial
Phase II Study of Ladarixin and Sotorasib In Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)Status: Withdrawn, Estimated PCD: 2025-04-01
Clinical trial
Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2025-08-01